The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) is scheduled to meet from 14 to 16 July 2026 to discuss applications for orphan designation. The meeting agenda, published by the EMA, indicates that the committee will evaluate requests for orphan medicinal product status, which grants incentives for developing treatments for rare diseases.
Orphan designation in the EU provides benefits such as protocol assistance, fee reductions, and ten years of market exclusivity upon approval. The COMP meeting is a routine quarterly gathering where members assess whether submitted applications meet the criteria for orphan status, including the prevalence of the condition (affecting no more than 5 in 10,000 people in the EU) and the potential for significant benefit over existing treatments.
Stakeholders impacted include pharmaceutical companies seeking orphan designation, which can lower development costs and provide market advantages. Patients with rare diseases may benefit from increased research and development of therapies. National health systems could face higher costs if orphan drugs are priced at a premium. The EMA itself manages the designation process, balancing incentives for innovation with ensuring patient access.
No specific applications or outcomes have been disclosed ahead of the meeting. The COMP will issue opinions following the three-day session, which will be published on the EMA website.